Neoplasms

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Carcinoma

Prostatic Neoplasms

Carcinoma, Renal Cell

Carcinoma, Transitional Cell

Testicular Neoplasms

Kidney Neoplasms

Penile Neoplasms

Urologic Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Genital Neoplasms, Male

Genital Diseases

Genital Diseases, Male

Endocrine Gland Neoplasms

Endocrine System Diseases

Testicular Diseases

Gonadal Disorders

Penile Diseases

Renal Cell Carcinoma

Transitional Cell Carcinoma

Penile Cancer

This is a prospective "n-of-1" type of trial where every patient is his/her own control. This is a study further developing the translational use of an existing framework and infrastructure for systematic sample collection an analytics previously established in the HUB project incorporating NGS and DSRT into clinical care.

Personalised treatment

Antti S Rannikko, MD, PhD

Antti s Rannikko, MD, PhD

Östling Päivi, PhD

Tuomas Mirtti, PhD

Petri Bono, PhD

Harry Nisen, PhD

Katriina Peltola, PhD

Olli Kallioniemi, PhD

Jukka Sairanen, PhD

Petrus Järvinen, PhD

Henrikki Santti, PhD

Anssi Petas, PhD

Mika Matikainen, PhD

Riikka Järvinen, PhD

Hanna Vasarainen, PhD

Tuomas Kilpeläinen, PhD

Mauri Kouri, PhD

Tapio Utriainen, PhD

Kimmo Taari, PhD

Vesa Rahkama, MSc

Andrew Erickson, MSc

Saeed Khalid, MSc

Maija Puhka, PhD

Vilja Pietiäinen, PhD

Lassi Paavolainen, MSc

Dmitry Bykhov, MSc

Teijo Pellinen, PhD

Sami Blom, MSc

Taija af Hällström, PhD

Kevin Sandeman, MD

Anu Kenttämies, PhD

Outi Oksanen, MD

Jarkko Pajarinen, PhD

Jari Siironen, PhD

The purpose of the study is to evaluate whether state-of-the-art technologies such and next generation sequencing and drug sensitivity and resistance testing of patient derived tumour tissue can facilitate research translation and improve outcome of urologic cancers.

Access to high-quality clinical patient material (e.g. tissue of primary tumor and metastasis, plasma and urine) linked to comprehensive registry and clinical data and molecular characterization of the patient material using state-of-the-art technologies (e.g. NGS, transcriptomics, imaging, DSRT) will facilitate a more rapid translation of basic research innovations into clinical care (diagnostics, imaging, therapeutics) and result in improved outcome of patients suffering from urologic cancers ("personalized medicine").

The principal aim of the project is to establish a framework and infrastructure for the systematic collection and interpretation of biological patient samples. Similarly, the investigators aim to establish the format how the related clinical and research data can be made readily accessible for both clinicians and researchers without compromising patient privacy. The key objectives of the project are to facilitate research translation and to improve outcome of urologic cancers.

Development of Diagnostics and Treatment of Urological Cancers

The magnitude of successful clinical translation is measured by the number of times project-derived personalized medicine has impacted patients care by application of novel and existing biomarkers and therapies (e.g. sequencing, DSRT) by 2020

Successful pre-clinical translation, the magnitude of which is measured by the number of times project-derived potential druggable targets or able to re-purpose treatment options were identified within the project by 2020.

Translation of preclinical data into clinically useful data. The success of which is measured by the number of times preclinical data (e.g. sequencing, DSRT) was transformed into clinically useful form within 4 weeks from the time the initial sampling of the specimen was done.

Representativeness is based on the genetics of the cell model and the parental tumor

Karolinska Institutet

Helsinki University Central Hospital

Senior consultant, urology

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Development of Diagnostics and Treatment of Urological Cancers	NCT02994758	Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer	Personalised tr...	18 Years -	Helsinki University Central Hospital
Development of Diagnostics and Treatment of Urological Cancers	NCT02994758	Prostate Carcin... Kidney Cancer Urothelial Carc... Testicular Canc... Penile Cancer	Personalised tr...	18 Years -	Helsinki University Central Hospital

Spots Global Cancer Trial Database for dsrt

Every month we try and update this database with for dsrt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for dsrt

Every month we try and update this database with for dsrt cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for dsrt cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.